Seattle Times – Delafield Hambrecht, a Seattle investment firm, is working to raise $100 million for a hedge fund focused on biotechnology stocks.
Launched earlier this month, the fund will be managed by Quynh Pham, a lauded stock-picker during her years with Delafield’s research department. She said the Delafield Hambrecht Biotechnology Fund initially will only invest in public companies and will be “geography agnostic.”
“Regardless of where companies are situated, we’re really looking for good investment ideas,” Pham said.
She’s keeping details of the investment strategy close to the vest.
Delafield Hambrecht shuttered its brokerage department, including stock trading and research, in December. The firm, which split off from San Francisco-based WR Hambrecht in early 2002, continues to offer asset management and investment banking.
